Stephen V. Liu, MD - Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical

Go online to PeerView.com/DDV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The broad implications of the expanding role of cancer immunotherapies in lung cancer necessitate multidisciplinary collaboration, especially in the locally advanced setting where appropriate patient evaluation and selection for immune checkpoint inhibitors (ICIs) along with other multimodal therapies requires input from a medical oncologist, a radiation oncologist, as well as a thoracic surgeon, among other specialists. Effective communication and coordination of care are also essential in the management of patients with unresectable stage III non–small cell lung cancer (NSCLC) deemed to be good candidates for consolidation ICI therapy after chemoradiation. How should this be operationalized in real-world settings? Learn useful strategies from this PeerView MasterClass and Tumor Board based on a recent web broadcast, which delivers evidence-based guidance on the best practices related to multidisciplinary patient assessment and treatment planning to help you improve outcomes in your patients with stage III NSCLC. Our panel of experts navigates through the latest evidence, key challenges, and controversies, as well as debates a series of real cases to demonstrate how to individualize patient care in the midst of rapid research and clinical advances. Upon completion of this activity, participants should be better able to: Discuss the latest clinical evidence on cancer immunotherapy in unresectable stage III NSCLC, Collaborate with relevant specialists to stage lung cancer, assess tumor resectability, and develop individualized treatment plans for patients with stage III NSCLC, Integrate cancer immunotherapies into the management of patients with unresectable stage III NSCLC according to the latest evidence and guidelines, multidisciplinary/interprofessional perspectives, and patient treatment and quality of life goals, Apply effective strategies to identify and manage immune-related adverse events in patients receiving cancer immunotherapy for unresectable stage III NSCLC treatment.